Arvinas's financial profile is defined by extreme volatility, with quarterly revenue swinging from $249.7M to $9.5M, indicating a business model heavily reliant on non-recurring milestone payments rather than predictable product sales. While gross margins cons...
Price trend, volume and key moving averages
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 4, 2026 | $2.58+789.6% vs -$0.37 | $250M+311.3% vs $61M |
Q2 2026 May 12, 2026 | -$0.90+5.3% vs -$0.95 | $16M-6.1% vs $17M |
Q1 2026 Feb 24, 2026 | -$1.10-100.0% vs -$0.55 | $10M-74.5% vs $37M |
Q4 2025 Nov 5, 2025 | -$0.48+36.0% vs -$0.75 | $42M+12.4% vs $37M |
– ARV-6723 is an investigational, oral PROTAC designed to degrade HPK1, a negative regulator of immune activation, in advanced solid tumors –
Arvinas, Inc. (ARVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that that management will participate in fireside chats at the following upcoming investor conferences:
NEW HAVEN, Conn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the Company granted 45,696 restricted stock units (“RSU”) to one newly hired employee (the “RSU Award”). The RSU Award was granted as of August 31, 2026 (the “Grant Date”) and in accordance with Nasdaq Listing Rule 5635(c)(4) and not pursuant to Arvinas' stock incentive plan.
Benchmark ARVN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Arvinas, Inc. (ARVN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $7.41 | $478.1M | -5.79 | -0.3% | -30.77% | -16.23% | — | |
| $107.39 | $8.83B | -29.10 | -16.72% | -285.41% | -21.5% | — | |
| $295.51 | $8.24B | -21.92 | -100% | — | -34.15% | — | |
| $499.40 | $11.51B | -38.86 | 432.05% | -25.32% | -56.65% | — | |
| $63.46 | $5.26B | 8.16 | 114.51% | -3.8% | — | — | |
| $24.44 | $3.07B | -7.43 | -4.26% | -386.32% | -87.98% | — |
Arvinas, Inc. (ARVN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Arvinas, Inc. (ARVN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 4, 2026·SEC
Jun 25, 2026·SEC
Jun 22, 2026·SEC
Get notified when ARVN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Arvinas, Inc. (ARVN) stock FAQ — growth, dividends, profitability & financials explained
Arvinas, Inc. (ARVN) reported $316.7M in revenue for fiscal year 2025. This represents a 4649% increase from $6.7M in 2016.
Arvinas, Inc. (ARVN) saw revenue decline by 0.3% over the past year.
Yes, Arvinas, Inc. (ARVN) is profitable, generating $9.3M in net income for fiscal year 2025 (-30.8% net margin).
Arvinas, Inc. (ARVN) has a return on equity (ROE) of -16.2%. Negative ROE indicates the company is unprofitable.
Arvinas, Inc. (ARVN) had negative free cash flow of $208.8M in fiscal year 2025, likely due to heavy capital investments.
